Skip to main content

How MVP looks like on Echocardiography

 

Mitral Valve Prolapse (MVP): The Click Behind the Murmur


Introduction

Mitral Valve Prolapse (MVP) is one of the most common valvular heart abnormalities encountered in clinical practice. It occurs when one or both mitral valve leaflets bulge backward into the left atrium during systole. While many patients remain asymptomatic throughout life, others may develop palpitations, arrhythmias, mitral regurgitation, or rarely sudden cardiac death.

With advancements in echocardiography, our understanding of MVP has evolved from a benign auscultatory curiosity to a clinically important structural heart disease with distinct phenotypes and risk profiles.


---

Anatomy of the Mitral Valve

The mitral valve apparatus consists of:

Anterior and posterior mitral leaflets

Mitral annulus

Chordae tendineae

Papillary muscles

Left ventricular myocardium


Proper coaptation of these structures ensures unidirectional blood flow from the left atrium to the left ventricle.

In MVP, leaflet redundancy, myxomatous degeneration, or chordal elongation leads to systolic displacement of the valve into the left atrium.


---

Definition of Mitral Valve Prolapse

Echocardiographically, MVP is defined as:

> Systolic displacement of one or both mitral valve leaflets ≥2 mm above the mitral annular plane into the left atrium in the parasternal long-axis view.



Two major forms are recognized:

Classic MVP

Leaflet thickness ≥5 mm

Marked myxomatous degeneration

Higher risk of complications


Non-classic MVP

Leaflet thickness <5 mm

Usually milder disease



---

Pathophysiology

The underlying mechanism commonly involves:

Myxomatous degeneration of leaflets

Excess leaflet tissue

Elongated or ruptured chordae tendineae

Annular dilatation


These changes produce leaflet billowing and incomplete closure during systole, potentially causing mitral regurgitation.

Over time, chronic volume overload may lead to:

Left atrial enlargement

Left ventricular dilatation

Atrial fibrillation

Pulmonary hypertension

Heart failure



---

Etiology and Associations

MVP may occur:

Primary (Degenerative)

Myxomatous degeneration

Fibroelastic deficiency


Secondary Associations

Marfan syndrome

Ehlers-Danlos syndrome

Osteogenesis imperfecta

Hypertrophic cardiomyopathy

Rheumatic involvement


Familial clustering is recognized in some patients.


---

Clinical Presentation

Many patients are asymptomatic and diagnosed incidentally.

Common Symptoms

Palpitations

Atypical chest pain

Fatigue

Dyspnea

Dizziness

Anxiety-like symptoms


Physical Examination

Classic auscultatory findings include:

Mid-systolic click

Late systolic murmur


The click results from sudden tensing of redundant leaflets and chordae.

Maneuvers that reduce LV volume (e.g., standing, Valsalva) make the click occur earlier.


---

Echocardiographic Evaluation

Echocardiography is the cornerstone for diagnosis and risk assessment.

Key Echo Findings

Leaflet prolapse into left atrium

Leaflet thickening or redundancy

Mitral regurgitation severity

Chordal rupture or flail leaflet

Left atrial and LV size

Annular disjunction


Important Views

Parasternal long-axis

Apical 4-chamber

Apical long-axis


3D echocardiography further improves anatomical characterization.


---

Mitral Annular Disjunction (MAD)

Mitral annular disjunction refers to separation between the mitral annulus and ventricular myocardium.

MAD has gained attention because of its association with:

Ventricular arrhythmias

Fibrosis

Sudden cardiac death in selected patients


Recognition of arrhythmic MVP is increasingly important in modern cardiology.


---

Arrhythmic MVP

A small subset of patients develop malignant ventricular arrhythmias.

High-Risk Features

Bileaflet prolapse

Mitral annular disjunction

Inferior T-wave inversion

Frequent PVCs

Complex ventricular ectopy

Papillary muscle fibrosis on cardiac MRI

Severe myxomatous disease


Symptoms may include:

Syncope

Presyncope

Sustained ventricular tachycardia


Holter monitoring and cardiac MRI may help risk stratification.


---

Complications

Potential complications include:

Mitral regurgitation

Chordal rupture

Infective endocarditis

Atrial fibrillation

Heart failure

Ventricular arrhythmias

Sudden cardiac death (rare)


Most patients, however, have an excellent prognosis.


---

Management

Treatment depends on symptoms and severity.

Asymptomatic Patients

Reassurance

Periodic echocardiographic follow-up


Symptomatic Patients

Beta blockers may help:

Palpitations

Anxiety symptoms

Hyperadrenergic states


Severe Mitral Regurgitation

Surgical repair is preferred when feasible.

Indications include:

Symptoms

LV dysfunction

LV dilatation

New atrial fibrillation

Pulmonary hypertension


Mitral valve repair generally provides excellent long-term outcomes.


---

Lifestyle and Prognosis

Most patients lead completely normal lives.

Recommendations include:

Regular follow-up

Blood pressure control

Exercise according to tolerance

Evaluation of unexplained syncope or arrhythmias


Routine antibiotic prophylaxis for endocarditis is no longer recommended solely for MVP.


---

Key Takeaways

MVP is a common valvular abnormality characterized by systolic leaflet displacement.

Echocardiography is essential for diagnosis and follow-up.

Most patients remain asymptomatic with excellent prognosis.

Severe MR and arrhythmic MVP represent important high-risk subsets.

Early recognition and timely intervention improve outcomes.



---

Conclusion

Mitral Valve Prolapse is far more than a simple midsystolic click. It represents a diverse spectrum ranging from benign incidental findings to advanced degenerative valve disease and arrhythmic syndromes. Modern imaging techniques have refined diagnosis, risk stratification, and treatment strategies.

Careful echocardiographic assessment, awareness of arrhythmic risk markers, and appropriate surveillance remain central to optimal patient care.


---



Comments

Popular posts from this blog

π˜Όπ™£π™©π™žπ™˜π™€π™–π™œπ™ͺπ™‘π™–π™©π™žπ™€π™£ π˜Όπ™›π™©π™šπ™§ π™Žπ™©π™§π™€π™ π™š

 π˜Όπ™£π™©π™žπ™˜π™€π™–π™œπ™ͺπ™‘π™–π™©π™žπ™€π™£ π˜Όπ™›π™©π™šπ™§ π™Žπ™©π™§π™€π™ π™š in  Patient with AF and acute IS/TIA European Heart Association Guideline recommends: • 1 days after TIA • 3 days after mild stroke • 6 days after moderate stroke • 12 days after severe stroke Early anticoagulation can decrease a risk of recurrent stroke and embolic events but may increase a risk of secondary hemorrhagic transformation of brain infarcts.  The 1-3-6-12-day rule is a known consensus with graded increase in delay of anticoagulation between 1 and 12 days after onset of ischemic stroke or transient ischemic attack(TIA), according to neurological severity based on European expert opinions. However, this rule might be somewhat later than currently used in a real-world practical setting.

Acute Treatment of Hyperkalemia

Acute Treatment of Hyperkalemia – A Practical, Bedside-Oriented Guide Hyperkalemia is a potentially life-threatening electrolyte abnormality that demands prompt recognition and decisive management. The danger lies not only in the absolute potassium value but in its effects on cardiac conduction, which can rapidly progress to fatal arrhythmias. Acute treatment focuses on three parallel goals: stabilizing the cardiac membrane, shifting potassium into cells, and removing excess potassium from the body. Understanding this stepwise approach helps clinicians act quickly and rationally in emergency settings. Why Hyperkalemia Is Dangerous Potassium plays a key role in maintaining the resting membrane potential of cardiac myocytes. Elevated serum potassium reduces the transmembrane gradient, leading to slowed conduction, ECG changes, ventricular arrhythmias, and asystole. Importantly, ECG changes do not always correlate with potassium levels, so treatment decisions should be based on clinical c...

2025 AHA/ACC Hypertension Guidelines Key points

  2025 AHA/ACC Hypertension Guidelines Explained: A Clear Summary for Clinicians and Students Hypertension remains one of the most significant contributors to cardiovascular morbidity and mortality worldwide. With continual refinement of evidence and risk-based strategies, the 2025 AHA/ACC Hypertension Guidelines bring an updated, practical approach that clinicians can use in daily practice. To make learning easier, I’ve created a clean and modern infographic summarizing all major recommendations. You can download it below and use it for study, teaching, or clinical reference. Download Infographic (PNG): 2025 Hypertension Guideline Infographic This post breaks down the key points from the guidelines and complements the infographic for a complete understanding. --- BP Categories: Understanding the Updated Thresholds The guidelines maintain the well-established classification of blood pressure: Normal: <120 / <80 Elevated: 120–129 / <80 Stage 1 Hypertension: 130–139 and/or 8...